EP 968B - Why We Age -- And Why We Don't Have To

“Aging is a disease, and that disease is treatable.”

Those are the words of Dr. David A. Sinclair, in his book, Lifespan: Why We Age?and Why We Don't Have To

Through his extensive research, Dr. Sinclair believes that we can slow down and even reverse aging. The key is activating newly discovered vitality genes, the descendants of an ancient genetic survival circuit that is both the cause of aging and the key to reversing it.

It's not even just about feeling younger, we can actually become younger. 

Dr. Sinclair joins Dr. Roizen to share insights from the book and explain some of the latest breakthrough discoveries in the science of longevity. 

Want better health and nutrition? Now you can get personalized supplement recommendations and custom vitamin packs delivered to your door! Go to PersonaNutrition.com/Roizen and take your free assessment and get 50% off your order today. - sponsor

Persona logo



 


Bonus
Could You Have a Heart Attack and Not Know It?
EP 968B - Why We Age -- And Why We Don't Have To
Featuring:
David A. Sinclair, PhD, AO
David A. Sinclair, PhD, AO, is Professor of Genetics at Harvard Medical School and Founding Director of the Paul F. Glenn Center for the Biological Mechanisms of Aging at Harvard. One of the leading innovators of his generation, he is listed by Time magazine as “one of the 100 most influential people in the world” (2014) and top 50 most important influential people in healthcare (2018).


He is a board member of the American Federation for Aging Research, a Founding Editor of the journal Aging, and has received more than 35 awards for his research on resveratrol, NAD, and reprogramming to reverse aging, which have been widely hailed as a major scientific breakthroughs.

In 2018, he became an Officer of the Order of Australia, the equivalent of a knighthood, for his work on national security matters and human longevity. Dr. Sinclair and his work have been featured on 60 Minutes, Today, The Wall Street Journal, The New York Times, Fortune, and Newsweek, among others.